Cerebral Amyloid Angiopathy Treatment Market Report 2026

The cerebral amyloid angiopathy treatment market size has grown strongly in recent years. It will grow from $2.24 billion in 2025 to $2.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to improved clinical understanding of amyloid-related disorders, increased diagnosis of age-related cerebrovascular conditions, expansion of neurology specialty centers, availability of advanced neuroimaging tools, growing use of antihypertensive therapies.

The cerebral amyloid angiopathy treatment market size is expected to see strong growth in the next few years. It will grow to $3.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising investments in neurodegenerative disease research, increasing adoption of personalized medicine approaches, expansion of monoclonal antibody pipelines, growing focus on early intervention strategies, improved clinical trial outcomes for amyloid-targeting drugs. Major trends in the forecast period include increasing development of anti-amyloid therapeutics, rising adoption of precision diagnostics for caa, growing focus on disease-modifying treatments, expansion of minimally invasive surgical interventions, enhanced emphasis on long-term supportive care.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the cerebral amyloid angiopathy treatment market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or peripheral nerves, resulting in impairments in movement, sensation, cognition, or other essential bodily functions. The rising incidence of neurological disorders is largely due to aging populations, lifestyle-related factors, environmental exposures, genetic susceptibility, and advances in diagnostic technologies. Cerebral amyloid angiopathy treatments support the management of neurological disorders by reducing amyloid accumulation in cerebral blood vessels, improving cerebral blood flow, and decreasing the risk of cognitive decline and stroke-related complications. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections estimating this number will increase to 13.8 million by 2060. Therefore, the rising burden of neurological disorders is fueling the growth of the cerebral amyloid angiopathy treatment market.

The increase in healthcare expenditure is also expected to propel the growth of the cerebral amyloid angiopathy treatment market going forward. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, hospital care, pharmaceuticals, and preventive services, by individuals, governments, and organizations. The growth in healthcare spending is driven by factors such as an aging population, the rising prevalence of chronic diseases, advancements in medical technologies, and increased demand for healthcare services and treatments. Cerebral amyloid angiopathy treatments contribute to healthcare efficiency by encouraging the development of targeted therapies, improving patient outcomes, and potentially reducing long-term care costs, thereby supporting more effective use of healthcare resources. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, U.S. healthcare spending rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, the rise in healthcare expenditure is contributing to the growth of the cerebral amyloid angiopathy treatment market.

Major companies operating in the cerebral amyloid angiopathy treatment market are concentrating on the development of innovative therapies, such as RNA interference (RNAi)-based treatments, to target disease-related gene expression and reduce amyloid accumulation in cerebral blood vessels. RNAi therapeutics are a class of drugs that leverage RNA interference mechanisms to silence specific genes, thereby preventing the production of proteins that contribute to disease progression. For instance, in July 2023, Alnylam Pharmaceuticals Inc., a US-based pharmaceutical company, announced plans to initiate the multiple-dose phase of its ALN-APP clinical trial in approved regions. The ALN-APP trial is designed to evaluate the safety and effectiveness of RNAi-based therapy in reducing amyloid precursor protein (APP) levels, which play a key role in amyloid plaque formation in the brain. By suppressing the gene responsible for APP production, the study aims to assess whether ALN-APP can slow or potentially reverse the progression of cerebral amyloid angiopathy (CAA).

Major companies operating in the cerebral amyloid angiopathy treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Limited, Merck & Co. Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Public Limited Company, Abbott Laboratories, GlaxoSmithKline plc, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International Limited, Viatris Incorporated, Biogen Idec Inc., Sandoz Group AG, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC, Lupin Limited, Glenmark Pharmaceuticals Limited, Alnylam Pharmaceuticals Incorporated, Amydis Inc.

North America was the largest region in the Largest cerebral amyloid angiopathy treatment market in 2025. The regions covered in the cerebral amyloid angiopathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cerebral amyloid angiopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cerebral amyloid angiopathy treatment market by increasing costs of imported biologics, diagnostic imaging equipment, surgical instruments, and advanced laboratory reagents used in diagnosis and treatment. Healthcare providers in North America and Europe are most affected due to reliance on specialized imported pharmaceuticals and devices, while Asia-Pacific faces higher costs in sourcing advanced diagnostics. These tariffs are contributing to higher treatment costs and delayed technology adoption. However, they are also encouraging domestic biopharmaceutical manufacturing, localized clinical research, and regional production of diagnostic tools, strengthening long-term treatment accessibility.

The cerebral amyloid angiopathy treatment market research report is one of a series of new reports that provides cerebral amyloid angiopathy treatment market statistics, including cerebral amyloid angiopathy treatment industry global market size, regional shares, competitors with a cerebral amyloid angiopathy treatment market share, detailed cerebral amyloid angiopathy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral amyloid angiopathy treatment industry. This cerebral amyloid angiopathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cerebral amyloid angiopathy (CAA) treatment refers to the clinical and therapeutic approaches used to manage and reduce the impact of CAA, a neurological disorder marked by the accumulation of amyloid-beta proteins within the walls of cerebral blood vessels. This condition elevates the risk of intracerebral hemorrhages, cognitive impairment, and dementia.

The main types of cerebral amyloid angiopathy (CAA) treatments include medication, therapeutic procedures, surgery, and supportive care. Medication-based treatment involves the use of drugs to control symptoms, slow disease progression, and manage associated conditions. These medications are delivered through routes such as oral, intravenous, or intramuscular administration and are prescribed for different patient groups, including geriatric, adult, and pediatric populations. Treatment is provided across healthcare settings including hospitals, clinics, and homecare environments.

The cerebral amyloid angiopathy treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, genetic testing services, biomarker testing services, and therapeutic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral amyloid angiopathy treatment market also includes sales of monoclonal antibodies, anti-inflammatory drugs, anticoagulants, antiplatelet therapy, and patient monitoring systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.